IE913601A1 - Megakaryocyte maturation factors - Google Patents
Megakaryocyte maturation factorsInfo
- Publication number
- IE913601A1 IE913601A1 IE360191A IE360191A IE913601A1 IE 913601 A1 IE913601 A1 IE 913601A1 IE 360191 A IE360191 A IE 360191A IE 360191 A IE360191 A IE 360191A IE 913601 A1 IE913601 A1 IE 913601A1
- Authority
- IE
- Ireland
- Prior art keywords
- mmf
- megakaryocyte
- maturation factor
- csf
- platelet
- Prior art date
Links
- 210000003593 megakaryocyte Anatomy 0.000 title claims description 125
- 230000035800 maturation Effects 0.000 title claims description 52
- 210000001772 blood platelet Anatomy 0.000 claims abstract description 139
- 238000000034 method Methods 0.000 claims abstract description 54
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 93
- 210000002966 serum Anatomy 0.000 claims description 49
- 102000004889 Interleukin-6 Human genes 0.000 claims description 22
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 206010043554 thrombocytopenia Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 13
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 12
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 102000000646 Interleukin-3 Human genes 0.000 claims description 11
- 108010002386 Interleukin-3 Proteins 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- -1 Meg-CSF Proteins 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 108091029865 Exogenous DNA Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000001361 thrombopoietic effect Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 208000007619 cyclic thrombocytopenia Diseases 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000035921 thrombopoiesis Effects 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000011132 hemopoiesis Effects 0.000 claims description 2
- 230000003039 myelosuppressive effect Effects 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 102100020880 Kit ligand Human genes 0.000 claims 2
- 101710177504 Kit ligand Proteins 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 208000014759 blood platelet disease Diseases 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 90
- 108090000190 Thrombin Proteins 0.000 description 65
- 229960004072 thrombin Drugs 0.000 description 65
- 239000006166 lysate Substances 0.000 description 33
- 108010094028 Prothrombin Proteins 0.000 description 32
- 102100027378 Prothrombin Human genes 0.000 description 32
- 229940039716 prothrombin Drugs 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 230000005764 inhibitory process Effects 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 22
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 21
- 108010067787 Proteoglycans Proteins 0.000 description 21
- 102000016611 Proteoglycans Human genes 0.000 description 21
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 229940100601 interleukin-6 Drugs 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 241000700199 Cavia porcellus Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 102000036693 Thrombopoietin Human genes 0.000 description 9
- 108010041111 Thrombopoietin Proteins 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 101710127913 Proteoglycan 4 Proteins 0.000 description 8
- 102100034195 Thrombopoietin Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000099 in vitro assay Methods 0.000 description 8
- 229940076264 interleukin-3 Drugs 0.000 description 8
- 108010091685 secretory granule proteoglycan Proteins 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 7
- 108090000394 Erythropoietin Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 208000013544 Platelet disease Diseases 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 229940105423 erythropoietin Drugs 0.000 description 7
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 102000007347 Apyrase Human genes 0.000 description 5
- 108010007730 Apyrase Proteins 0.000 description 5
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 5
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 101150001634 mmf1 gene Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000007625 Hirudins Human genes 0.000 description 3
- 108010007267 Hirudins Proteins 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 229960002376 chymotrypsin Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229940006607 hirudin Drugs 0.000 description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108020002447 serine esterase Proteins 0.000 description 3
- 102000005428 serine esterase Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical group OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005074 megakaryoblast Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003582 thrombocytopenic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- YIJFIIXHVSHQEN-UHFFFAOYSA-N 3-Aminocaproic acid Chemical compound CCCC(N)CC(O)=O YIJFIIXHVSHQEN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100334117 Caenorhabditis elegans fah-1 gene Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010058423 Haemangioma-thrombocytopenia syndrome Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000010299 Kasabach-Merritt syndrome Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940097597 bothrops atrox venom Drugs 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- RJYSYRSELCQCSO-UHFFFAOYSA-M cesium;2,2,2-trifluoroacetate Chemical compound [Cs+].[O-]C(=O)C(F)(F)F RJYSYRSELCQCSO-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 108010050939 thrombocytin Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59645790A | 1990-10-12 | 1990-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE913601A1 true IE913601A1 (en) | 1992-04-22 |
Family
ID=24387345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE360191A IE913601A1 (en) | 1990-10-12 | 1991-10-16 | Megakaryocyte maturation factors |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0505552A4 (fr) |
| JP (1) | JPH05503302A (fr) |
| AU (1) | AU8868891A (fr) |
| CA (1) | CA2071479A1 (fr) |
| IE (1) | IE913601A1 (fr) |
| IL (1) | IL99648A0 (fr) |
| WO (1) | WO1992006712A1 (fr) |
| ZA (1) | ZA918070B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922572A (en) | 1994-01-25 | 1999-07-13 | Human Genome Sciences, Inc. | Polynucleotides encoding haemopoietic maturation factor |
| US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| EP0675201A1 (fr) * | 1994-03-31 | 1995-10-04 | Amgen Inc. | Compositions et procédés pour la stimulation de la croissance et la différenciation des mégacaryocytes |
| WO1998001151A1 (fr) * | 1996-07-10 | 1998-01-15 | Meiji Milk Products Co., Ltd. | Nouvelle utilisation de la famille mk comme facteur hematopoietique |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404717B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| AP2138A (en) * | 2004-04-14 | 2010-07-22 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes. |
| CN1968695A (zh) * | 2004-04-14 | 2007-05-23 | 细胞基因公司 | 含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法 |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB2146335A (en) * | 1983-09-07 | 1985-04-17 | Ej Ass Inc | Wound healing compositions |
| US4894440A (en) * | 1986-09-17 | 1990-01-16 | Massachusetts Institute Of Technology | Method of isolating megakaryocyte stimulatory factor |
| IL90719A0 (en) * | 1988-06-28 | 1990-01-18 | Yissum Res Dev Co | Novel nuclei acids and polypeptides encoded thereby |
| JPH04500904A (ja) * | 1988-07-13 | 1992-02-20 | ブリガム・アンド・ウイメンズ・ホスピタル | 免疫応答のエフェクター細胞のヒトプロテオグリカンペプチドコアをコードしているポリヌクレオチド |
| JPH04506513A (ja) * | 1989-04-03 | 1992-11-12 | ジェネティックス・インスティテュート・インコーポレイテッド | 巨核球増殖促進活性 |
-
1991
- 1991-10-02 EP EP19910919689 patent/EP0505552A4/en not_active Withdrawn
- 1991-10-02 CA CA002071479A patent/CA2071479A1/fr not_active Abandoned
- 1991-10-02 WO PCT/US1991/007367 patent/WO1992006712A1/fr not_active Application Discontinuation
- 1991-10-02 JP JP3518291A patent/JPH05503302A/ja active Pending
- 1991-10-02 AU AU88688/91A patent/AU8868891A/en not_active Abandoned
- 1991-10-04 IL IL99648A patent/IL99648A0/xx unknown
- 1991-10-09 ZA ZA918070A patent/ZA918070B/xx unknown
- 1991-10-16 IE IE360191A patent/IE913601A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2071479A1 (fr) | 1992-04-13 |
| ZA918070B (en) | 1992-07-29 |
| IL99648A0 (en) | 1992-08-18 |
| EP0505552A4 (en) | 1994-06-08 |
| AU8868891A (en) | 1992-05-20 |
| WO1992006712A1 (fr) | 1992-04-30 |
| JPH05503302A (ja) | 1993-06-03 |
| EP0505552A1 (fr) | 1992-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markwardt | Development of hirudin as an antithrombotic agent | |
| Markwardt | Past, present and future of hirudin | |
| US6090916A (en) | Nematode-extracted serine protease inhibitors and anticoagulant proteins | |
| EP0041766B1 (fr) | Nouveau activateur de plasminogène et composition pharmaceutique à activité thrombolytique | |
| EP0477274B1 (fr) | COMPOSITIONS ANTICOAGULANTES A BASE DE FACTEUR Xa | |
| US5547931A (en) | Methods of stimulatory thrombocytopoiesis using modified C-reactive protein | |
| Jochum et al. | Clotting and other plasma factors in experimental endotoxemia: Inhibition of degradation by exogenous proteinase inhibitors | |
| EP0196920B1 (fr) | Espèce dégradée d'activateur de plasminogène tissulaire, composition pharmaceutique et sa méthode de préparation | |
| IE913601A1 (en) | Megakaryocyte maturation factors | |
| US5236705A (en) | Fibrinolysis | |
| RO106890B1 (ro) | VARIANTE DE HIRUDINã ©I PROCEDEU DE PREPARARE A ACESTORA | |
| Haag-Weber et al. | Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins | |
| EP0208486B1 (fr) | Procédé de préparation d'un plasminogène activateur de tissu | |
| US5656484A (en) | Protein S deletion variants deficient in C4BP binding activity but having APC cofactor activity compositions and therapeutic methods | |
| FI110669B (fi) | Menetelmiä luonnosta eristettävissä tai synteettisesti valmistettavissa olevien trombiini-inhibiittorien valmistamiseksi | |
| JP2003521919A (ja) | プロテインｃ誘導体 | |
| KR100260964B1 (ko) | Tcf-ii를 유효성분으로 하는 혈액응고 정상화제 | |
| EP0517925A1 (fr) | Nouvel amplificateur de megakaryocyte et sa production | |
| US5955294A (en) | Nematode-extracted serine protease inhibitors and anticoagulant proteins | |
| EP0672684A1 (fr) | Nouveau facteur de stimulation de colonies megacaryocytaires et production de ce facteur | |
| CZ245598A3 (cs) | Způsob výroby rDSPA alfa 1 | |
| NZ537271A (en) | A method of inhibiting blood or serum coagulation in vitr | |
| Huat et al. | Biochemical characterization of an in-vitro murine megakaryocyte growth activity: megakaryocyte potentiator | |
| AU2010222537B2 (en) | Use of serine protease inhibitors in the treatment of neutropenia | |
| CN101041690B (zh) | 重组犬钩虫抗凝肽5突变体、其编码基因、其制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Application refused sect. 31(1) |